AbbVie sidelines CytomX after seeing midphase oncology ADC data, opens talks on returning lead drug

AbbVie sidelines CytomX after seeing midphase oncology ADC data, opens talks on returning lead drug

Source: 
Fierce Biotech
snippet: 

AbbVie has ditched its pact with CytomX Therapeutics. After seeing 83% of patients in the latest data cut develop anemia, the Big Pharma has dropped the cancer program for strategic portfolio reasons—and begun negotiating to sell the lead antibody-drug conjugate (ADC) back to CytomX.